BioCryst Pharmaceuticals, Inc. (BCRX)Healthcare | Drug Manufacturers - Specialty & Generic | Durham, United States | NasdaqGS
9.82 USD
-0.05
(-0.507%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.82 |
Hot Take ↕ | Aug. 22, 2026, 4:17 a.m. EDT
The immediate catalyst here is the aggressive options positioning, which screams 'breakout' potential. Traders are stacking call open interest at strikes significantly higher than the current price, creating a distinct gamma exposure that could fuel a rapid move if the stock clears the $10 resistance. This aligns with the recent price action where the stock has reclaimed key moving averages and is trading near its 52-week highs. However, the long-term picture remains a study in contrasts. While the business fundamentals are actually quite robust—showing a 33.6% revenue surge, healthy gross margins, and a fortress-like cash position—the stock has been punished by the market for years. The price history reveals a brutal decade-long decline punctuated by volatility, suggesting the market has deeply discounted the company's potential despite its operational success. The disconnect between the strong underlying metrics and the depressed valuation creates a compelling case for a turnaround trade, but the path forward is likely to be choppy as the market digests the transition from a distressed asset to a growth story. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.042707 |
| AutoETS | 0.042708 |
| AutoTheta | 0.043734 |
| MSTL | 0.046468 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.191 |
| Excess Kurtosis | 0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 4.099 |
| Market Cap | 2,509,354,752 |
| Forward P/E | 10.45 |
| Beta | 0.55 |
| Profit Margins | -40.90% |
| Website | https://www.biocryst.com |
As of Aug. 22, 2026, 4:17 a.m. EDT: Speculators are heavily positioned for upside, evidenced by massive open interest in out-of-the-money calls (strikes 13 and 15) compared to negligible put volume. The call chain shows significant volume at strikes well above the current price, while put activity is sparse and concentrated near the money, indicating a bullish bias rather than hedging.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.1845597 |
| Address1 | 4,505 Emperor Boulevard |
| Address2 | Suite 200 |
| All Time High | 37.25 |
| All Time Low | 0.6 |
| Ask | 11.19 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 2,335,160 |
| Average Daily Volume3 Month | 4,325,747 |
| Average Volume | 4,325,747 |
| Average Volume10Days | 2,335,160 |
| Beta | 0.554 |
| Bid | 8.44 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | -1.78 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.82 |
| Current Ratio | 2.321 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 9.96 |
| Day Low | 9.72 |
| Display Name | BioCryst Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,933,000 |
| Earnings Call Timestamp Start | 1,785,933,000 |
| Earnings Growth | 14.0 |
| Earnings Quarterly Growth | 14.417 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | 433,047,008 |
| Ebitda Margins | 0.46039 |
| Enterprise To Ebitda | 6.912 |
| Enterprise To Revenue | 3.182 |
| Enterprise Value | 2,993,426,688 |
| Eps Current Year | 0.745 |
| Eps Forward | 0.94 |
| Eps Trailing Twelve Months | -1.39 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 919 859 1314 |
| Fifty Day Average | 9.698 |
| Fifty Day Average Change | 0.12199974 |
| Fifty Day Average Change Percent | 0.012579886 |
| Fifty Two Week Change Percent | 18.45597 |
| Fifty Two Week High | 11.22 |
| Fifty Two Week High Change | -1.4000006 |
| Fifty Two Week High Change Percent | -0.124777235 |
| Fifty Two Week Low | 6.0 |
| Fifty Two Week Low Change | 3.8199997 |
| Fifty Two Week Low Change Percent | 0.6366666 |
| Fifty Two Week Range | 6.0 - 11.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 762,791,400,000 |
| Float Shares | 222,356,427 |
| Forward Eps | 0.94 |
| Forward P E | 10.446808 |
| Free Cashflow | 323,666,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 435 |
| Fullday Change | -0.0500002 |
| Fullday Change Percent | -0.506588 |
| Fullday Price | 9.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.77388 |
| Gross Profits | 727,923,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01195 |
| Held Percent Institutions | 1.05275 |
| Implied Shares Outstanding | 255,535,105 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investor.shareholder.com/biocryst/index.cfm |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
| Long Name | BioCryst Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,509,354,752 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_25594 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -384,672,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,520,853,810 |
| Number Of Analyst Opinions | 11 |
| Open | 9.822 |
| Operating Cashflow | 376,135,008 |
| Operating Margins | 0.45116 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 9.39 |
| Phone | 919 859 1302 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 9.82 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 9.87 |
| Price Eps Current Year | 13.181208 |
| Price Hint | 2 |
| Price To Book | -5.516854 |
| Price To Sales Trailing12 Months | 2.6677866 |
| Profit Margins | -0.40895998 |
| Quick Ratio | 2.219 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.45455 |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -0.506588 |
| Regular Market Day High | 9.96 |
| Regular Market Day Low | 9.72 |
| Regular Market Day Range | 9.72 - 9.96 |
| Regular Market Open | 9.822 |
| Regular Market Previous Close | 9.87 |
| Regular Market Price | 9.82 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 2,702,936 |
| Return On Assets | 0.52861 |
| Revenue Growth | 0.336 |
| Revenue Per Share | 4.099 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 255,535,105 |
| Shares Percent Shares Out | 0.1289 |
| Shares Short | 32,939,174 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 31,208,457 |
| Short Name | BioCryst Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1299 |
| Short Ratio | 9.31 |
| Source Interval | 15 |
| State | NC |
| Symbol | BCRX |
| Target High Price | 32.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 20.81818 |
| Target Median Price | 17.0 |
| Total Cash | 352,572,992 |
| Total Cash Per Share | 1.38 |
| Total Debt | 836,644,992 |
| Total Revenue | 940,612,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.49995 |
| Two Hundred Day Average Change | 1.3200493 |
| Two Hundred Day Average Change Percent | 0.15530083 |
| Type Disp | Equity |
| Volume | 2,702,936 |
| Website | https://www.biocryst.com |
| Zip | 27,703 |